

## Special Issue

# Glioblastoma in Adults: Current Management and Future Directions

### Message from the Guest Editors

As you know, glioma is the most common primary tumor of the central nervous system, and is characterized by rapid growth and aggressiveness; glioblastoma is one of the most dreaded brain tumors. There has been a commitment to drug development and new treatments for glioma, but progress has been limited, and the prognosis for patients with GBM remains poor. Inherent or acquired resistance to existing therapies, regional and heterogeneous blood glioma barriers, and the number of stem-cell-like cells within glioblastomas are challenges that are being actively addressed. These new approaches need to be summarized, especially regarding fundamental oncology approaches, and in the light of the new WHO brain tumor classification of 2021.

### Guest Editors

Dr. Thomas Graillon

Department of Neurosurgery, Hospital La Timone, Aix Marseille Univ, APHM, Marseille, France

Dr. Sebastien Boissonneau

Department of Neurosurgery, Hospital La Timone, Aix Marseille Univ, APHM, Marseille, France

### Deadline for manuscript submissions

closed (31 October 2023)



## Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 3.3  
Indexed in PubMed



[mdpi.com/si/132691](https://mdpi.com/si/132691)

*Current Oncology*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/curroncol)  
[curroncol](https://curroncol)





# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 3.3  
Indexed in PubMed



[mdpi.com/journal/  
currentcol](https://mdpi.com/journal/currentcol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility

: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)